Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly

Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, compared with 926 previously. Fifty-four institutions have now ordered the cutaneous T-cell lymphoma treatment, up from the 44 reported in the company’s last update.

The figures indicate expanding distribution, but wholesaler purchases and institutional orders measure different stages of the supply chain. Revenue is recognized when wholesaler orders are fulfilled, after applicable adjustments; the release did not provide net revenue or profit. The unit figures remain unaudited and may change during year-end closing. Citius Pharmaceuticals ($CTXR) has indirect exposure as Citius Oncology’s majority owner. Full fiscal-year and fourth-quarter results are expected in December.

Sources:

• PR Newswire